United Kingdom

People: Cerus Corp (CERS.OQ)

CERS.OQ on NASDAQ Stock Exchange Global Market

4:44pm BST
Change (% chg)

$0.14 (+2.63%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Bjerkholt, Eric 

Mr. Eric H. Bjerkholt is Independent Director of the Company, Mr. Bjerkholt has served as a member of our Board since October 2018. Since April 2017, Mr. Bjerkholt has been the Chief Financial Officer of Aimmune Therapeutics, Inc., a biotechnology company developing treatments for food allergies. From 2004 until April 2017, Mr. Bjerkholt held various roles at Sunesis Pharmaceuticals, Inc., a biopharmaceutical company developing oncology therapeutics, including as Executive Vice President, Corporate Development and Finance and Chief Financial Officer. From 2002 to 2004, he was Senior Vice President and Chief Financial Officer at IntraBiotics Pharmaceuticals, Inc., a biopharmaceutical company that was acquired by Ardea Biosciences, Inc. in 2006. Mr. Bjerkholt was a co-founder of LifeSpring Nutrition, Inc., a nutraceutical company, and from 1999 to 2002 served at various times as its Chief Executive Officer, President, and Chief Financial Officer. From 1990 to 1997, he also served as a vice president in the healthcare banking group at J.P. Morgan & Co. Incorporated, an international banking firm. He has served on the boards of directors of several publicly traded companies, including as a member of the board of directors and chair of the audit committee of Corium International, Inc. until its acquisition by Gurnet Point Capital in November 2018, and as a member of the board of directors and as chair of the audit committee of StemCells, a biotech company, until its November 2016 acquisition by Microbot Medical Ltd. He holds a Cand. Oecon degree in Economics from the University of Oslo and an M.B.A. from Harvard Business School.

Basic Compensation

Total Annual Compensation, USD 12,815
Restricted Stock Award, USD 86,954
Long-Term Incentive Plans, USD --
All Other, USD 83,464
Fiscal Year Total, USD 183,233

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Daniel Swisher


William Greenman


Kevin Green


Carol Moore


William Moore


Laurence Corash

As Of  31 Dec 2018